

**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Edmund
Tracy-Gene C. Durkin
Michele A. Cimbalà
Michael B. Ray
Robert E. Sokol
Eric K. Stoffer
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Hanner
Robert C. Millington
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Jodi L. Kraus
Olson L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Judman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Gurst
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
Lukene M. Desantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabry L. Longworth
Len A. Gordon
Laura A. Vogel
Bryan S. Wade
Bachir M.S. Ali
Shannon A. Camell
Matthew E. Kelley
Michelle K. Hekubek
Marsha A. Rose

Christopher J. Walsh
W. Blake Coblenz
James J. Pohl
Young Tang
John T. Harari
Mark W. Rygiel

Registered Patent Agents
Karen R. Marowicz
Matthew J. Dowd
Kazuma Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Buchford
Simon J. Elliott
Julie A. Heider
Mita Washbenjee
Scott M. Woodhouse

Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Of Counsel
Edward J. Kessler
Kenneth C. Bass II
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice limited to
Federal Agencies

July 13, 2006

WRITER'S DIRECT NUMBER:

(202) 773-8523

INTERNET ADDRESS:

BRIAND@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1636

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Appl. No. 10/551,054; § 371 Date: September 23, 2005
(U.S. National Phase of Intl. Appl. No. PCT/EP04/003164); I.A. Date: March 25, 2004)
For: **Melan-A-Carrier Conjugates**
Inventors: **Martin F. BACHMANN et al.**
Our Ref: 1700.0590000/BJD/WBC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08B (9 pages) citing eighty-three (83) documents;
3. Copies of eighty-three (83) cited documents: NPL1-NPL83;
4. Form PTO-1449 (9 pages) citing sixty-seven (67) documents;
5. Copies of forty-three (43) cited documents: AL1-AP1; AL2-AP2; AL3-AP3; AL4-AP4; AL5-AP5; AL6-AP6; AL3-AP3; AL4-AP4; AL5-AP5; AL6-AP6; AL7-AP7; AL8-AP8; and AL9-AN9; and
6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents

July 13, 2006

Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

BJD/WBC:cpn

Enclosures

556628_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Martin F. BACHMANN *et al.*

Appl. No.: 10/551,054
(U.S. National Phase of Intl. Appl. No.
PCT/EP04/003164)

Filed: September 23, 2005
(Int'l Filing Date: March 25, 2004)

For: **Melan-A-Carrier Conjugates**

Confirmation No.: 1432

Art Unit: 1636

Examiner: *To Be Assigned*

Atty. Docket: 1700.0590000/BJD/WBC

**Information Disclosure Statement
Filing Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO-1449 and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents **AL1-AN9** and **NPL1-NPL83** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **AA1-AB3**, cited on the attached Form PTO-1449 are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **AO1** and **AO3** cited on Form PTO-1449:

Document **AO1**, EP 0 201 416 B1, is in the French language. An English language abstract of document **AO1** is attached as document **NPL83**.

Document **AO3**, WO 98/58751 A1, is in the French language. An English language abstract of document AO3 is located on the face page of said document.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date:

July 13, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

514634_1.DOC



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1700.0590000/BJD/WBC

APPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)

FIRST NAMED INVENTOR
Bachmann, M.

PCT FILING DATE
March 25, 2004

ART UNIT
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
/MM/	AA1	4,722,840	02/02/1988	Valenzuela <i>et al.</i>			09/19/1985
	AB1	4,959,314	09/25/1990	Mark <i>et al.</i>			02/07/1985
	AC1	5,143,726	09/01/1992	Thornton <i>et al.</i>			11/20/1989
	AD1	5,565,548	10/15/1996	Neurath <i>et al.</i>			03/15/1993
	AE1	5,698,424	12/16/1997	Mastico <i>et al.</i>			§ 371 Date: 01/03/1995
	AF1	5,844,075	12/01/1998	Kawakami and Rosenberg			04/05/1995
	AG1	5,874,560	02/23/1999	Kawakami and Rosenberg			04/22/1994
	AH1	5,935,821	08/10/1999	Chatterjee <i>et al.</i>			11/21/1996
	AI1	5,939,598	08/17/1999	Kucherlapali <i>et al.</i>			07/30/1992
	AJ1	5,994,523	11/30/1999	Kawakami and Rosenberg			01/16/1998
	AK1	6,025,470	02/15/2000	Valmori <i>et al.</i>			06/23/1997

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
/MM/	✓ AL1	EP 0 038 154 B1	10/21/1981	Europe			Yes No
	✓ AM1	EP 0 385 610 B1	03/16/1994	Europe			Yes No
	✓ AN1	EP 0 421 635 A1	04/10/1991	Europe			Yes No
	✓ AO1	EP 0 201 416 B1	04/10/1991	Europe			Yes No
	AP1	WO 92/13081 A1	08/06/1992	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		
AS		
AT		

EXAMINER /Mary Mosher/

DATE CONSIDERED 12/31/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
/MM/	AA2	6,231,864 B1	05/15/2001	Birkett			02/11/1999
	AB2	6,270,778 B1	08/07/2001	Kawakami and Rosenberg			03/12/1999
	AC2	6,277,956 B1	08/21/2001	Valmori et al.			04/16/1998
	AD2	6,326,200 B1	12/04/2001	Valmori et al.			06/18/1998
	AE2	6,368,857 B1	04/09/2002	Valmori et al.			10/05/1999
	AF2	6,380,364 B1	04/30/2002	Mueller et al.			10/06/1999
	AG2	6,384,190 B1	05/07/2002	Valmori et al.			12/14/1999
	AH2	6,627,202 B2	09/30/2003	Murray			06/04/2001
	AI2	2003/0050268 A1	03/13/2003	Krieg and Berg			03/29/2002
	AJ2	6,537,560 B1	03/25/2003	Kawakami and Rosenberg			05/05/1998
	AK2	2003/0082804 A1	05/01/2003	Valmori et al.			02/21/2001

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
/MM/	AL2	EP 0 578 293 A1	01/12/1994	Europe			Yes
	AM2	WO 94/14969 A1	07/07/1994	WIPO			No
	AN2	WO 95/29193 A2	11/02/1995	WIPO			No
	AO2	WO 96/30523 A2	10/03/1996	WIPO			No
	AP2	WO 98/40100 A1	09/17/1998	WIPO			No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	
	AS	
	AT	

EXAMINER

/Mary Mosher/

DATE CONSIDERED 12/31/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)

FIRST NAMED INVENTOR

Bachmann, M.

PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
/MM/ ↓	AA3	6,719,978 B2	04/13/2004	Schiller et al.			04/13/2001
	AB3	6,965,017 B2	11/15/2005	Kawakami and Rosenberg			07/03/2001
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
/MM/ ↓	AL3	WO 98/49195 A1	11/05/1998	WIPO			Yes No
	AM3	WO 98/50071 A1	11/12/1998	WIPO			Yes No
	AN3	WO 98/58951 A1	12/30/1998	WIPO			Yes No
	AO3	WO 98/58751 A1	12/30/1998	WIPO			Yes No
	AP3	WO 99/28478 A1	06/10/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER /Mary Mosher/

DATE CONSIDERED 12/31/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)INFORMATION DISCLOSURE STATEMENTFIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
/MM/	AL4	WO 99/40934 A1	08/19/1999	WIPO			Yes No
	AM4	WO 99/57289 A2	11/11/1999	WIPO			Yes No
	AN4	WO 00/23955 A1	04/27/2000	WIPO			Yes No
	AO4	WO 00/32227 A2	06/08/2000	WIPO			Yes No
	AP4	WO 00/37610 A2	06/29/2000	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER /Mary Mosher/

DATE CONSIDERED 12/31/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)INFORMATION DISCLOSURE STATEMENTFIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
MM ↓	AL5	WO 00/39304 A2	07/06/2000	WIPO			Yes No
	AM5	WO 00/50461 A1	08/31/2000	WIPO			Yes No
	AN5	WO 00/62800 A2	10/26/2000	WIPO			Yes No
	AO5	WO 01/16320 A1	03/08/2001	WIPO			Yes No
	AP5	WO 01/22972 A2	04/05/2001	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

/Mary Mosher/

DATE CONSIDERED 12/31/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
/MM/	AL6	WO 01/22990 A2	04/05/2001	WIPO			Yes No
	AM6	WO 01/56603 A1	08/09/2001	WIPO			Yes No
	AN6	WO 01/58478 A1	08/16/2001	WIPO			Yes No
	AO6	WO 01/77158 A1	10/18/2001	WIPO			Yes No
	AP6	WO 01/85208 A2	11/15/2001	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	
	AS	
	AT	

EXAMINER /Mary Mosher/	DATE CONSIDERED 12/31/2007
---------------------------	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)INFORMATION DISCLOSURE STATEMENTFIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
/MM/	AL7	WO 01/98333 A2	12/27/2001	WIPO			Yes No
↓	AM7	WO 02/14478 A2	02/21/2002	WIPO			Yes No
	AN7	WO 02/053141 A2	07/11/2002	WIPO			Yes No
	AO7	WO 02/056905 A2	07/25/2002	WIPO			Yes No
↓	AP7	WO 02/056907 A2	07/25/2002	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER /Mary Mosher/

DATE CONSIDERED 12/31/2007


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)FIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
- /MM/	AL8	WO 03/024480 A2	03/27/2003	WIPO			Yes No
	AM8	WO 03/024481 A2	03/27/2003	WIPO			Yes No
	AN8	WO 03/031466 A2	04/17/2003	WIPO			Yes No
	AO8	WO 03/039225 A2	05/15/2003	WIPO			Yes No
	AP8	WO 03/040164 A2	05/15/2003	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

/Mary Mosher/

DATE CONSIDERED 12/31/2007


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
1700.0590000/BJD/WBCAPPLICATION NO.
10/551,054 (National Phase of
Intl. Appl. No. PCT/EP04/003164)INFORMATION DISCLOSURE STATEMENTFIRST NAMED INVENTOR
Bachmann, M.PCT FILING DATE
March 25, 2004ART UNIT
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
/MM/	AL9	WO 03/059386 A2	07/24/2003	WIPO			Yes No
	AM9	WO 04/000351 A1	12/31/2003	WIPO			Yes No
	AN9	WO 04/007538 A2	01/22/2004	WIPO			Yes No
							Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER /Mary Mosher/

DATE CONSIDERED 12/31/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
/MM/	NPL1	Adams, S.E., et al., "The expression of hybrid HIV-Ty virus-like particles in yeast," <i>Nature</i> 329:68-70, Nature Publishing Group (1987)		
	NPL2	Addo, M.M., et al., "Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load," <i>J. Virol.</i> 77:2081-2092, American Society for Microbiology (February 2003)		
	NPL3	Bachmann, M.F., and Zinkernagel, R., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunol. Today</i> 17:553-558, Elsevier Science (1996)		
	NPL4	Bachmann, M.F., and Zinkernagel, R.M., "Neutralizing Antiviral B Cell Responses," <i>Ann. Rev. Immunol.</i> 15:235-270, Annual Reviews, Inc. (1997)		
	NPL5	Brown, W.L., et al., "RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation," <i>Intervirology</i> 45:371-380, S. Karger AG (July-December 2002)		
	NPL6	Buonaguro, L., et al., "High efficient production of Pr55 ^{gag} virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A," <i>Antiviral Res</i> 49:35-47, Elsevier Science B.V. (2001)		
	NPL7	Chackerian, B., et al., "Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles," <i>Proc. Natl. Acad. Sci. USA</i> 96:2373-2378, The National Academy of Sciences (1999)		
	NPL8	Chen, J.L., et al., "Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL," <i>J. Immunol.</i> 165:948-55, The American Association of Immunologists (2000)		
	NPL9	Cohen, P.A., et al., "CD4 ⁺ T-Cells from Mice Immunized to Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens," <i>Cancer Research</i> 54:1055-8, American Association for Cancer Research (1994)		
	NPL10	De Clercq, E., "Interferon Induction by Polynucleotides, Modified Polynucleotides, and Polycarboxylates," <i>Methods Enzymol.</i> 78:227-36, Academic Press, Inc. (1981)		

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
/MM/	NPL11	Dudley, M.E., et al., "Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes," <i>Science</i> 298:850-854, American Association for the Advancement of Science (October 2002)		
	NPL12	Engleman, E.G., "Dendritic cells: Potential role in cancer therapy," <i>Cytotechnol.</i> 25:1-8, Kluwer Academic Publishers (1997)		
	NPL13	Fehr, T., et al., "Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies," <i>J. Exp. Med.</i> 185:1785-92, The Rockefeller University Press (1997)		
	NPL14	Fehr, T., et al., "T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles," <i>Proc. Natl. Acad. Sci. USA</i> 95:9477-9481, The National Academy of Sciences (1998)		
	NPL15	Firat, H., et al., "H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," <i>Eur. J. Immunol.</i> 29:3112-3121, WILEY-VCH Verlag GmbH (1999)		
	NPL16	Fitch, J., et al., "Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response," <i>Vaccine</i> 13:1051-1057, Elsevier Science (1995)		
	NPL17	Gerber, S., et al., "Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with <i>Escherichia coli</i> Heat-Labile Enterotoxin Mutant R192G or CpG DNA," <i>J. Virol.</i> 75:4752-60, American Society for Microbiology (2001)		
	NPL18	Geysen, H.M., et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002, The National Academy of Sciences (1984)		
	NPL19	Gilbert, S.C., et al., "A protein particle vaccine containing multiple malaria epitopes," <i>Nat. Biotechnol.</i> 15:1280-1284, Nature America Publishing (1997)		
	NPL20	Gluckman, J.C., et al., "In vitro generation of human dendritic cells and cell therapy," <i>Cytokines Cell. Mol. Ther.</i> 3:187-96, Martin Dunitz Ltd. (1997)		

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	3	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
/MM/	NPL21	Golmohammadi, R., et al., "The crystal structure of bacteriophage Q β at 3.5 Å resolution," <i>Structure</i> 4:543-554, Current Biology Ltd. (1996)		
	NPL22	Graff-Dubois, S., et al., "Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy," <i>J. Immunol.</i> 169:575-580, The American Association of Immunologists, Inc. (July 2002)		
	NPL23	Harada, M., et al., "Use of an <i>in Vitro</i> Immunoselected Tumor Line to Identify Shared Melanoma Antigens Recognized by HLA-A*0201-restricted T Cells," <i>Cancer Res.</i> 61:1089-1094, American Association for Cancer Research (2001)		
	NPL24	Huston, J.S., et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," <i>Methods Enzymol.</i> 203:46-88, Academic Press, Inc. (1991)		
	NPL25	Jegerlehner, A., et al., "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," <i>Vaccine</i> 20:3104-3012, Elsevier Science Ltd. (August 2002)		
	NPL26	Kalsho, T. and Akira, S., "Toll-like receptors as adjuvant receptors," <i>Biochim. Biophys. Acta</i> 1589:1-13, Elsevier Science (February 2002)		
	NPL27	Kang, C.Y., et al., "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-Like Particles," <i>Biol. Chem.</i> 380:353-64, Walter De Gruyter (1999)		
	NPL28	Klinman, D.M., et al., "Immunotherapeutic Applications of CpG-Containing Oligodeoxynucleotides," <i>Drug News Perspect.</i> 13:289-296, Prous Science (2000)		
	NPL29	Klovins, J., et al., "Nucleotide sequence of a ssRNA phage from <i>Acinetobacter</i> : kinship to coliphages," <i>J. Gen. Virol.</i> 83:1523-1533, SGM (June 2002)		
	NPL30	Kobayashi H., et al., "Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient," <i>Immunogenet.</i> 47:398-403, Springer-Verlag (1998)		

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time varies depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	4	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
/MM/	NPL31	Kobayashi, H., et al., "Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles," <i>Cancer Res.</i> 61:4773-4778, American Association for Cancer Research (2001)		
	NPL32	Kozlovskaya, T. M., et al., "RNA Phage Q β Coat Protein as a Carrier for Foreign Epitopes," <i>Interviol.</i> 39:9-15, S. Karger AG Basel (1996)		
	NPL33	Kozlovskaya, T.M., et al., "Recombinant RNA phage Q β capsid particles synthesized and self-assembled in <i>Escherichia coli</i> ," <i>Gene</i> 137:133-137, Elsevier Science Publishers B.V. (1993)		
	NPL34	Kratz, P.A., et al., "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," <i>Proc. Natl. Acad. Sci. USA</i> 96:1915-1920, The National Academy of Sciences (1999)		
	NPL35	Krug, A., et al., "Identification of CpG oligonucleotide sequences with high induction of IFN- α/β in plasmacytoid dendritic cells," <i>Eur. J. Immunol.</i> 31:2154-63, WILEY Verlag GmbH (2001)		
	NPL36	Kuramoto, E., et al., "Oligonucleotide Sequences Required for Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-1131, Japanese Cancer Association (1992)		
	NPL37	Lechner, F., et al., "Virus-like Particles as a Modular System for Novel Vaccines," <i>Interviol.</i> 45:212-217, S. Karger AG (July-December 2002)		
	NPL38	Levy, H.B., "Induction of Interferon <i>in Vivo</i> and <i>in Vitro</i> by Polynucleotides and Derivatives, and Preparation of Derivatives," <i>Methods Enzymol.</i> 78:242-51, Academic Press, Inc. (1981)		
	NPL39	Li, Y., et al., "Vaccination Against Angiogenesis-Associated Antigens: A Novel Cancer Immunotherapy Strategy," <i>Curr. Mol. Med.</i> 3:773-779, Bentham Science Publishers Ltd. (December 2003)		
	NPL40	Linette, G.P., et al., "In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8 ⁺ T cells in Patients with Melanoma," <i>J. Immunol.</i> 164:3402-3412, The American Association of Immunologists (2000)		

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	5	of	9	Attorney Docket Number	1700.059000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
/MM/	NPL41	Luo, L., et al., "Induction of V3-Specific Cytotoxic T Lymphocyte Responses by HIV gag Particles Carrying Multiple Immunodominant V3 Epitopes of gp120," <i>Virol.</i> 240:316-325, Academic Press (1998)		
	NPL42	Malling, H.-J., and Taudorf, E., "Allergenicity of alum-precipitated grass pollen extracts with different RAST activity," <i>Clin. Allergy</i> 17:399-404, Blackwell Scientific Publications (1987)		
	NPL43	Martin, S.J., et al., "Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses," <i>AIDS</i> 7:1315-23, Current Science Ltd. (1993)		
	NPL44	Moss, R.B., et al., "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides," <i>Vaccine</i> 18:1081-7, Elsevier Science Ltd. (2000)		
	NPL45	Neirynck, S., et al., "A universal influenza A vaccine based on the extracellular domain of the M2 protein," <i>Nature Med.</i> 5:1157-63, Nature Publishing Company (1999)		
	NPL46	Nieland, J.D., et al., "Chimeric Papillomavirus Virus-like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response," <i>J. Cell. Biochem.</i> 73:145-152, Wiley-Liss, Inc. (1999)		
	NPL47	Nielsen, M.B., et al., "Status of Activation of Circulating Vaccine-Elicited CD8 ⁺ T Cells," <i>J. Immunol.</i> 165:2287-96, The American Association of Immunologists (2000)		
	NPL48	Notka, F., et al., "Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies," <i>Vaccine</i> 18:291-301, Elsevier Science Ltd. (2000)		
	NPL49	Nussbaum, A.K., et al., "PAProC: a prediction algorithm for proteasomal cleavages available on the WWW," <i>Immunogenet.</i> 53:87-94, Springer-Verlag (2001)		
	NPL50	Oxenius, A., et al., "CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines," <i>J. Virol.</i> 73:4120-4126, American Society for Microbiology (1999)		

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	6	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
/MM/	NPL51	Panelli, M.C., et al., "Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases," <i>J. Immunol.</i> 164:495-504, The American Association of Immunologists (2000)		
	NPL52	Parkhurst, M.R., et al., "Identification of a Shared HLA-A*0201-restricted T-Cell Epitope from the Melanoma Antigen Tyrosinase-related Protein 2 (TRP2)," <i>Cancer Res.</i> 58:4895-4901, American Association for Cancer Research (1998)		
	NPL53	Pasek, M., et al., "Hepatitis B virus genes and their expression in <i>E. coli</i> ," <i>Nature</i> 282:575-579, Macmillan Journals Ltd. (1979)		
	NPL54	Pass, H.A., et al., "Immunization of Patients with Melanoma Peptide Vaccines: Immunologic Assessment Using the ELISPOT Assay," <i>Cancer J. Sci. Am.</i> 4:316-323, Scientific American, Inc. (1998)		
	NPL55	Pumpens, P. and Grens, E., "HBV Core Particles as a Carrier for B Cell/T Cell Epitopes," <i>Intervirology</i> 44:98-114, S. Karger AG (2001)		
	NPL56	Pushko, P., et al., "Analysis of RNA phage <i>fr</i> coat protein assembly by insertion, deletion and substitution mutagenesis," <i>Protein Eng.</i> 6:883-891, Oxford University Press (1993)		
	NPL57	Rammensee, H., et al., "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenet.</i> 50:213-219, Springer-Verlag (1999)		
	NPL58	Roth, J.F., "The yeast Ty virus-like particles," <i>Yeast</i> 16:785-795, John Wiley & Sons, Ltd. (2000)		
	NPL59	Rueda, P., et al., "Minor Displacements in the Insertion Site Provoke Major Differences in the Induction of Antibody Responses by Chimeric Parvovirus-like Particles," <i>Virology</i> 263:89-99, Academic Press (1999)		
↓	NPL60	Sallusto, F. and Lanzavecchia, A., "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α ," <i>J. Exp. Med.</i> 179:1109-1118, The Rockefeller University Press (1994)		

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	7	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/MM/	NPL61	Salunke, D.M., et al., "Self-Assembly of Purified Polyomavirus Capsid Protein VP1," <i>Cell</i> 46:895-904, Cell Press (1986)	
	NPL62	Sasnauskas, K., et al., "Yeast Cells Allow High-Level Expression and Formation of Polyomavirus-Like Particles," <i>Biol. Chem.</i> 380:381-6, Walter de Gruyter (1999)	
	NPL63	Skipper, J.C.A., et al., "Mass-Spectrometric Evaluation of HLA-A*0201-Associated Peptides Identifies Dominant Naturally Processed Forms of CTL Epitopes from MART-1 and gp100," <i>Int. J. Cancer</i> 82:669-677, Wiley-Liss Inc. (1999)	
	NPL64	Slepushkin, V.A., et al., "Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein," <i>Vaccine</i> 13:1399-1402, Elsevier Science (1995)	
	NPL65	Smiley, B.K. and Minion, F.C., "Enhanced readthrough of opal (UGA) stop codons and production of <i>Mycoplasma pneumoniae</i> P1 epitopes in <i>Escherichia coli</i> ," <i>Gene</i> 134:33-40, Elsevier Science Publishers B.V. (1993)	
	NPL66	Sparwasser, T., et al., "Immunostimulatory CpG-Oligodeoxynucleotides Cause Extramedullary Murine Hemopoiesis," <i>J. Immunol.</i> 162:2368-2374, The American Association of Immunologists (1999)	
	NPL67	Speiser, D.E., et al., "In vivo activation of melanoma-specific CD8 ⁺ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells," <i>Eur. J. Immunol.</i> 32:731-741, WILEY-VCH Verlag GmbH (March 2002)	
	NPL68	Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exp. Hematol.</i> 24:859-862, Elsevier Science Inc. (1996)	
	NPL69	Storni, T., et al., "Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles," <i>J. Immunol.</i> 168:2880-2886, The American Association of Immunologists (March 2002)	
	NPL70	Sun, Y., et al., "Identification of a New HLA-A*0201-Restricted T-Cell Epitope from the Tyrosinase-Related Protein 2 (TRP2) Melanoma Antigen," <i>Int. J. Cancer</i> 87:399-404, Wiley-Liss Inc. (2000)	

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EPO4/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	8	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/MM/	NPL71	Taylor, K.M., <i>et al.</i> , "Position-Dependent Processing of Peptides Presented on the Surface of Cowpea Mosaic Virus," <i>Biol. Chem.</i> 380:387-392, Walter de Gruyter (1999)	
	NPL72	Toes, R.E., <i>et al.</i> , "Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products," <i>J. Exp. Med.</i> 194:1-12, The Rockefeller University Press (2001)	
	NPL73	Torrence, P.F., "Preparation of a Synthetic Polynucleotide Interferon Inducer," <i>Meth. Enzymol.</i> 78:326-331, Academic Press, Inc. (1981)	
	NPL74	Touzé, A., <i>et al.</i> , "Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells," <i>J. Gen. Virol.</i> 82:3005-3009, Society for General Microbiology (2001)	
	NPL75	Valmori, D., <i>et al.</i> , "Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues," <i>J. Immunol.</i> 160:1750-1758, The American Association of Immunologists (1998)	
	NPL76	Valmori, D., <i>et al.</i> , "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," <i>J. Immunol.</i> 161:6956-6962, The American Association of Immunologists (1998)	
	NPL77	van Schooten, W.C.A., <i>et al.</i> , "Biological properties of dendritic cells: implications to their use in the treatment of cancer," <i>Mol. Med. Today</i> 255:254-260, Elsevier Science (1997)	
	NPL78	Vasiljeva, I., <i>et al.</i> , "Mosaic Q β coats as a new presentation model," <i>FEBS Lett</i> 431:7-11, Elsevier Science B.V. (1998)	
	NPL79	Witte, L., <i>et al.</i> , "Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy," <i>Cancer Metastasis Rev.</i> 17:155-161, Kluwer Academic Publishers (1998)	
✓	NPL80	Yuan, T.T., <i>et al.</i> , "Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen," <i>J. Virol.</i> 73:10122-10128, American Society for Microbiology (1999)	

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/551,054 (National Phase of Intl. Appl. No. PCT/EP04/003164)
				PCT Filing Date	March 25, 2004
				First Named Inventor	Martin F. BACHMANN
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	9	of	9	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
/MM/	NPL81	Zarour, H.M., et al., "NY-ESO-1 119-143 Is a Promiscuous Major Histocompatibility Complex Class II T-Helper Epitope Recognized by Th1- and Th2-Type Tumor-reactive CD4 ⁺ T Cells," <i>Cancer Res.</i> 62:213-218, American Association for Cancer Research (January 2002)		
↓	NPL82	Zhou, S. and Standing, D.N., "Cys Residues of the Hepatitis B Virus Capsid Protein Are Not Essential for the Assembly of Viral Core Particles but Can Influence Their Stability," <i>J. Virol.</i> 66:5393-5398, American Society for Microbiology (1992)		
↓	NPL83	Dialog File 351, Accession No. 4796523, Derwent WPI English language abstract for EP 0 201 416 A1, cited as document AO1 on Form PTO-1449		

514074_1.DOC

Examiner Signature	/Mary Mosher/	Date Considered	12/31/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.